XPhyto announces European Approval for 25 Minute COVID-19 PCR Test
Mar 18, 2021
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2Rapid results with ease of use - single 20-minute PCR cycle plus...
We’re a leading bioscience company focused on accelerating new and innovative medical solutions for positive impact.
Stay up to date. Find out about our latest research, products, exclusive partnerships and more.
XPhyto brings together cutting-edge companies and top researchers from around the world to innovate, accelerate and commercialize disruptive technology, from drug delivery formulations to diagnostics.
Innovative and Cutting-Edge Solutions
Precision transdermal and oral drug formulations
Point-of-care (POC) diagnostics including rapid infectious disease screening
Production, formulation and validation of new active pharmaceutical ingredients (APIs)
Our research and innovation have the potential to impact lives around the world.
Learn more about how XPhyto products could change the lives of people suffering from conditions and how our new research may impact the state of our global community.
Mar 18, 2021
CE Mark received for in vitro diagnostic (IVD) test for the detection of SARS-CoV-2Rapid results with ease of use - single 20-minute PCR cycle plus...
Mar 10, 2021
Vancouver, Canada (March 10, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), and its exclusive German diagnostics development partner,...
Mar 4, 2021
Vancouver, Canada (March 4, 2021) - XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”), is pleased to announce that the Company...
Learn more about XPhyto’s innovation to impact strategy and get access to XPhyto investor information.
CSE:XPHY FSE:4XT OTCQB:XPHYF